HLB Pharmaceutical Co Ltd

HLB Pharmaceutical Co Ltd maintains a relatively strong capital structure, with a debt-to-equity ratio of 0.17, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 1.94, suggesting it can cover its short-term liabilities with its current assets. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

In terms of profitability, HLB Pharmaceutical Co Ltd reports a return on equity (ROE) of 3.65% and a return on assets (ROA) of 2.68%. These figures are below the typical thresholds for high-performing pharmaceutical firms, indicating that the company may not be generating returns as efficiently as its peers. The operating margin, calculated as operating income of 4,654.07 million KRW on revenue of 205,581.74 million KRW, is 2.26%, which is relatively low for the industry.

HLB Pharmaceutical Co Ltd's revenue is concentrated in a single business segment, as disclosed in its financial reports, with no material geographic diversification beyond South Korea. This concentration increases the company's exposure to domestic market conditions and regulatory changes, which could impact its revenue stability.

The company's growth trajectory is modest, with no significant revenue growth reported in the latest financial period. The capital expenditure of -7,210.49 million KRW indicates a net outflow, which may suggest a reduction in investment in new projects or facilities. The outlook for the current fiscal year does not indicate a substantial increase in revenue or profitability, and the next fiscal year is expected to follow a similar trend.

HLB Pharmaceutical Co Ltd faces a low risk of dilution, with no significant dilution potential identified in the latest financial data. The company's risk assessment highlights the negative net cash position as a key flag, which could affect its ability to meet short-term obligations without external financing. No recent events, such as major filings or transcripts, have been identified that would significantly alter the company's risk profile.

HLB Pharmaceutical Co Ltd has not disclosed any recent major events, such as earnings calls, regulatory filings, or strategic announcements, that would provide insight into its operational or financial performance beyond what is already reflected in its financial statements.